Rockland Trust Co. Purchases 21,739 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Rockland Trust Co. increased its stake in Thermo Fisher Scientific by 66.3%, owning 54,525 shares valued at $22.1 million as of the latest SEC filing.
• Insider trading included notable sales by CAO Joseph R. Holmes and CEO Marc N. Casper, with both reducing their holdings by 14.24% and 0.35%, respectively, in recent transactions.
• Thermo Fisher Scientific reported Q2 earnings that exceeded estimates, with a revenue of $10.86 billion and guidance for Q3 2025 EPS set at 5.460-5.510.

Rockland Trust Co. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 66.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 54,525 shares of the medical research company's stock after purchasing an additional 21,739 shares during the quarter. Rockland Trust Co.'s holdings in Thermo Fisher Scientific were worth $22,108,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of TMO. Mondrian Investment Partners LTD grew its holdings in shares of Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares during the last quarter. Foresight Group Ltd Liability Partnership grew its holdings in shares of Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock worth $29,113,000 after acquiring an additional 56,747 shares during the last quarter. Advisors Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after acquiring an additional 7,967 shares during the last quarter. Ilmarinen Mutual Pension Insurance Co grew its holdings in shares of Thermo Fisher Scientific by 5.3% in the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock worth $33,488,000 after acquiring an additional 3,400 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after acquiring an additional 877 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TMO. Evercore ISI lowered their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $490.00 to $550.00 in a report on Thursday, September 11th. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Finally, Robert W. Baird lifted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $588.35.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last three months. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $1.08 during mid-day trading on Friday, reaching $480.02. The company had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company's 50-day moving average is $472.01 and its 200-day moving average is $449.50. The company has a market capitalization of $181.26 billion, a P/E ratio of 27.76, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.